Wellesley Pharmaceuticals Overview
- Founded
- 2011
- Status
- Private
- Employees
- 1
- Latest Deal Type
- Series D
- Latest Deal Amount
- $10M
- Investors
- 2
Wellesley Pharmaceuticals General Information
Description
Developer of a drug designed to treat nocturia. The company's patented drug assist in treating the frequent need to urinate at night and to eliminate nocturia symptoms which can be disseminated, enabling patients to sleep well at night without using the bathroom.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- 18111 Cornerstone Drive
- Yardley, PA 19067
- United States
+1 (908) 000-0000
Wellesley Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series D) | 18-Apr-2016 | $10M | 000.00 | 0000 | Completed | Clinical Trials - Phase 2 |
| 3. Later Stage VC (Series C) | 01-Apr-2015 | 00.00 | 00.000 | 0000 | Completed | Clinical Trials - Phase 2 |
| 2. Angel (individual) | 01-Oct-2014 | $550K | $1.05M | 000.00 | Completed | Clinical Trials - Phase 2 |
| 1. Angel (individual) | 11-Jun-2014 | $500K | $500K | 000.00 | Completed | Clinical Trials - Phase 2 |
Wellesley Pharmaceuticals Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| David Dill | Founder, Chief Executive Officer, President & Chairman |
Wellesley Pharmaceuticals Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Dill | Wellesley Pharmaceuticals | Founder, Chief Executive Officer, President & Chairman | 000 0000 |
| John Balian | Wellesley Pharmaceuticals | Board Member | 000 0000 |
| Michael Myers Ph.D | Self | Board Member | 000 0000 |
Wellesley Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialWellesley Pharmaceuticals Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Axella Bioventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Keiretsu Forum | Venture Capital | Minority | 000 0000 | 000000 0 |